REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-Biomarker analysis.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2018
This article has no abstract
Epistemonikos ID: a464b8000ccc4ba2a65ba223f6fd29008ccfa53a
First added on: Feb 01, 2023